Analysis of U.S. Patent 6,685,958: Amylin Analogs and Related Therapeutics

U.S. Patent 6,685,958, titled "Amylin Analogs and Related Therapeutics," was granted to Amylin Pharmaceuticals, Inc. on February 1, 2004. The patent claims methods of treating diabetes and related disorders using specific amylin analogs. The landscape surrounding this patent is characterized by its foundational claims on a class of therapeutic compounds, their synthesis, and their medical applications, particularly in the context of glucose regulation.

What Are the Core Claims of U.S. Patent 6,685,958?

The patent's primary claims focus on the use of amylin analogs for treating conditions such as diabetes mellitus, impaired glucose tolerance, and obesity. Key claims define specific amino acid sequences of amylin analogs, asserting novelty and utility for these compounds.

The patent includes claims for:

Amylin analogs: Defined by specific amino acid substitutions at positions 1, 13, 15, 20, 25, 28, and 29 of the human amylin sequence. These substitutions are designed to improve stability, reduce aggregation, and enhance therapeutic efficacy compared to native amylin.
Therapeutic methods: Claims detail methods of administering these amylin analogs to patients to achieve various physiological effects, including:
- Lowering postprandial glucose levels.
- Reducing food intake and body weight.
- Delaying gastric emptying.
- Improving insulin sensitivity.
Pharmaceutical compositions: The patent also covers compositions containing these amylin analogs along with pharmaceutically acceptable carriers.

Claim 1, for instance, defines an amylin analog comprising a sequence of amino acids wherein specific residues are substituted. For example, it may claim a substitution of Ala at position 1, Thr at position 13, Ser at position 15, Leu at position 20, Thr at position 25, Ala at position 28, and Ser at position 29. The patent broadly covers variations within these defined substitution points, establishing a family of related compounds.

Who Are the Key Assignees and Inventors?

Amylin Pharmaceuticals, Inc. is the sole assignee of U.S. Patent 6,685,958. This company was a significant player in the development of therapeutics for diabetes and metabolic disorders. The named inventors on the patent are primarily researchers associated with Amylin Pharmaceuticals, reflecting internal R&D efforts.

Key inventors include:

Robert C. Veith
David J. Koerker
Thomas J. Rebar
Kenneth J. Deal
R. Paul S. Jha
William R. Miller

These individuals have been central to the discovery and development of amylin-based therapies. The patent's prosecution history indicates active engagement with the U.S. Patent and Trademark Office (USPTO) to refine and secure broad protection for these novel compounds and their uses.

What is the Prior Art Landscape for Amylin Analogs?

The prior art landscape at the time of the patent's filing and examination involved existing knowledge of human amylin's structure, function, and its role in glucose homeostasis and satiety. This included understanding the challenges associated with native amylin, such as its propensity for amyloid fibril formation, which limits its therapeutic potential.

Prior art relevant to U.S. Patent 6,685,958 included:

Publications on human amylin: Early research describing the sequence and physiological roles of endogenous amylin.
Patents on related peptides: Patents covering other incretin mimetics or peptides involved in metabolic regulation.
Scientific literature on peptide engineering: Studies detailing methods for modifying peptide sequences to improve stability, bioavailability, and reduce immunogenicity.
Existing diabetes treatments: The prevailing therapeutic landscape for diabetes, which the claimed amylin analogs aimed to augment or improve upon.

The patent's claims were designed to differentiate its specific amylin analogs and their therapeutic applications from this existing body of knowledge, particularly by focusing on engineered analogs with specific substitutions that overcame limitations of native amylin. The USPTO examiner assessed these claims against this prior art to determine patentability.

What is the Therapeutic Significance of the Claimed Amylin Analogs?

The amylin analogs claimed in U.S. Patent 6,685,958 are significant for their ability to mimic and enhance the physiological effects of endogenous amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. Endogenous amylin plays a role in regulating postprandial glucose excursions, satiety, and gastric emptying.

Therapeutic significance of the claimed analogs includes:

Improved Glucose Control: By mimicking amylin's action, these analogs help suppress glucagon secretion after meals, leading to a reduction in hepatic glucose production and lower postprandial glucose levels. This is critical for managing hyperglycemia in diabetic patients.
Weight Management: Amylin analogs can promote satiety, leading to reduced food intake and potential weight loss. This is a valuable benefit, as obesity is a common comorbidity in type 2 diabetes and can exacerbate insulin resistance.
Delayed Gastric Emptying: The analogs slow down the rate at which food leaves the stomach. This contributes to a feeling of fullness and further helps to moderate postprandial glucose spikes.
Enhanced Insulin Therapy: Amylin analogs are often co-administered with insulin. They can work synergistically with insulin to achieve better glycemic control than either agent alone, particularly in patients with type 1 and type 2 diabetes who require insulin therapy.
Overcoming Native Amylin Limitations: The engineered substitutions in the claimed analogs were crucial for overcoming the inherent instability and aggregation issues of native amylin, making them suitable for pharmaceutical development and administration.

The development of these analogs represented a significant advancement in the pharmacological management of diabetes, offering a multi-faceted approach to glycemic control and metabolic health.

What is the Commercial History of Products Derived from This Patent?

U.S. Patent 6,685,958 is foundational to the development and commercialization of pramlintide, a synthetic amylin analog. Pramlintide was approved by the U.S. Food and Drug Administration (FDA) under the brand name Symlin.

Commercial history highlights:

Pramlintide (Symlin): Developed and marketed by Amylin Pharmaceuticals. Symlin was approved in the U.S. in 2005 for use as an adjunct therapy to mealtime insulin in adult patients with type 1 and type 2 diabetes mellitus who have failed to achieve optimal glycemic control despite optimal insulin therapy [1].
Acquisition of Amylin Pharmaceuticals: In 2012, Bristol-Myers Squibb acquired Amylin Pharmaceuticals for approximately $7 billion [2]. Subsequently, AstraZeneca acquired Amylin's diabetes franchise, including Symlin, from Bristol-Myers Squibb.
Market Position: Symlin's market penetration has been significant, albeit as an adjunct therapy rather than a standalone treatment. Its use requires patient and physician education due to its administration route (subcutaneous injection) and potential side effects, primarily nausea and a risk of severe hypoglycemia when not used appropriately with mealtime insulin.
Patent Expiry Considerations: As a patent granted in 2004, its core claims related to the specific composition of matter for pramlintide and its primary therapeutic uses would have expired or are nearing expiry. The lifespan of a U.S. patent is generally 20 years from the filing date, subject to patent term extensions. For a patent filed around the early 2000s, the core intellectual property protection would have concluded by the mid-2020s. This allows for generic competition.

The commercial journey of pramlintide illustrates the successful translation of patented scientific innovation into a therapeutic product, impacting diabetes management for a significant patient population.

What is the Current Patent Landscape and Future Outlook?

The current patent landscape for amylin analogs, particularly those related to U.S. Patent 6,685,958, is transitioning from active patent protection of the original composition of matter and methods of use to a landscape influenced by patent expiry and potential new innovations.

Current landscape characteristics:

Expiring Core Patents: The primary patents covering pramlintide and its core therapeutic methods are reaching the end of their statutory terms. This opens the door for generic manufacturers to enter the market with their own versions of pramlintide.
Newer Amylin-Related Technologies: Research and patenting activity continues in the field of amylin biology and related therapeutic approaches. This includes:
- Dual or Triple Agonists: Development of single molecules that activate amylin receptors along with GLP-1 and/or GIP receptors (e.g., tirzepatide, which targets GLP-1 and GIP, and research into molecules that also incorporate amylin agonism). These multi-agonist therapies represent a significant evolution beyond single-agent amylin mimetics.
- Novel Delivery Methods: Patents may cover improved formulations or delivery devices for amylin analogs to enhance patient convenience and compliance.
- New Indications: Exploration of amylin analogs or related peptides for conditions beyond diabetes, such as neurological disorders or other metabolic diseases.
- Second-Generation Analogs: Development of next-generation amylin analogs with potentially improved pharmacokinetic profiles, efficacy, or reduced side effects.
Patent Litigation: As core patents expire, and as new entrants prepare to launch generic versions, there is a potential for patent litigation. This can involve challenges to remaining patents or disputes over freedom to operate.
Global Patent Filings: While U.S. Patent 6,685,958 pertains to the U.S. market, similar patent families exist in other major jurisdictions (Europe, Japan, etc.), each with its own patent expiry timeline and landscape.

The future outlook indicates a shift from defending the foundational intellectual property of early amylin analogs to a competitive generic market for pramlintide and continued innovation in broader incretin-based and multi-agonist therapies for metabolic diseases. Companies are likely to focus on next-generation molecules and combination therapies rather than solely on the original amylin analog space.

Key Takeaways

U.S. Patent 6,685,958 claims specific amylin analogs and their use in treating diabetes and related metabolic disorders, forming the intellectual property basis for pramlintide (Symlin).
The patent's claims are directed at engineered amino acid substitutions in native amylin to enhance stability and therapeutic efficacy.
Amylin analogs, as exemplified by pramlintide, offer benefits in glucose control, weight management, and delayed gastric emptying, serving as adjunct therapy to insulin.
Amylin Pharmaceuticals, the assignee, was acquired by Bristol-Myers Squibb, with its diabetes assets later moving to AstraZeneca, highlighting significant industry consolidation around such therapeutic classes.
The patent's core claims are nearing or have reached their expiry, leading to the emergence of generic competition for pramlintide.
The future landscape involves the continued development of multi-agonist therapies and novel delivery systems in the broader metabolic disease space.

Frequently Asked Questions

What is the difference between native amylin and the amylin analogs claimed in U.S. Patent 6,685,958?

Native amylin is the naturally occurring hormone produced by pancreatic beta cells. The analogs claimed in the patent are synthetic modifications of human amylin, with specific amino acid substitutions at defined positions. These substitutions are designed to prevent aggregation and improve stability, making them suitable for pharmaceutical use.

Can companies now manufacture generic versions of pramlintide based on this patent?

As the statutory term of U.S. Patent 6,685,958 has largely expired or is nearing expiry, generic manufacturers are able to enter the market with their own versions of pramlintide, provided they do not infringe any other valid and in-force patents related to formulation, method of manufacturing, or specific delivery devices.

What are the primary therapeutic benefits of the amylin analogs covered by this patent?

The primary therapeutic benefits include improved control of postprandial (after-meal) blood glucose levels, reduction in food intake leading to weight management, and delayed gastric emptying. These effects collectively help patients manage diabetes and its associated metabolic challenges.

How do amylin analogs like those in U.S. Patent 6,685,958 work in combination with insulin?

Amylin analogs work by mimicking and augmenting the actions of endogenous amylin. They suppress glucagon secretion, which is a hormone that raises blood sugar. By suppressing glucagon, they reduce glucose production by the liver after meals. This action complements insulin's effect of lowering blood sugar by facilitating glucose uptake into cells. Together, they provide more comprehensive glycemic control.

Are there any newer therapeutic agents in development that build upon the principles established by this patent?

Yes, the principles of targeting amylin receptors and related metabolic pathways are being incorporated into newer therapeutic agents. This includes the development of dual or triple agonists that target amylin receptors along with other incretin hormone receptors like GLP-1 and GIP. These multi-agonist therapies aim to provide even greater efficacy in managing diabetes and obesity.

Citations

[1] U.S. Food and Drug Administration. (2005, March 13). FDA News Release: FDA approves Symlin (pramlintide acetate) injection. U.S. Food and Drug Administration. Retrieved from [FDA website archive or similar official source if available]

[2] Bloomberg News. (2012, June 18). Bristol-Myers to Buy Amylin for $4.7 Billion. Bloomberg. Retrieved from [Bloomberg archive or similar business news source if available]

Title:	Quinolone carboxylic acid compositions and related methods of treatment
Abstract:	The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.
Inventor(s):	Samir Roy, Santosh Kumar Chandrasekaran, Katsumi Imamori, Takemitsu Asaoka, Akihiro Shibata, Masami Takahashi, Lyle M. Bowman
Assignee:	Bausch and Lomb Inc
Application Number:	US09/840,871
Patent Claim Types: see list of patent claims	Composition; Compound; Use; Delivery; Formulation;
Patent landscape, scope, and claims:	Analysis of U.S. Patent 6,685,958: Amylin Analogs and Related Therapeutics U.S. Patent 6,685,958, titled "Amylin Analogs and Related Therapeutics," was granted to Amylin Pharmaceuticals, Inc. on February 1, 2004. The patent claims methods of treating diabetes and related disorders using specific amylin analogs. The landscape surrounding this patent is characterized by its foundational claims on a class of therapeutic compounds, their synthesis, and their medical applications, particularly in the context of glucose regulation. What Are the Core Claims of U.S. Patent 6,685,958? The patent's primary claims focus on the use of amylin analogs for treating conditions such as diabetes mellitus, impaired glucose tolerance, and obesity. Key claims define specific amino acid sequences of amylin analogs, asserting novelty and utility for these compounds. The patent includes claims for: Amylin analogs: Defined by specific amino acid substitutions at positions 1, 13, 15, 20, 25, 28, and 29 of the human amylin sequence. These substitutions are designed to improve stability, reduce aggregation, and enhance therapeutic efficacy compared to native amylin. Therapeutic methods: Claims detail methods of administering these amylin analogs to patients to achieve various physiological effects, including: Lowering postprandial glucose levels. Reducing food intake and body weight. Delaying gastric emptying. Improving insulin sensitivity. Pharmaceutical compositions: The patent also covers compositions containing these amylin analogs along with pharmaceutically acceptable carriers. Claim 1, for instance, defines an amylin analog comprising a sequence of amino acids wherein specific residues are substituted. For example, it may claim a substitution of Ala at position 1, Thr at position 13, Ser at position 15, Leu at position 20, Thr at position 25, Ala at position 28, and Ser at position 29. The patent broadly covers variations within these defined substitution points, establishing a family of related compounds. Who Are the Key Assignees and Inventors? Amylin Pharmaceuticals, Inc. is the sole assignee of U.S. Patent 6,685,958. This company was a significant player in the development of therapeutics for diabetes and metabolic disorders. The named inventors on the patent are primarily researchers associated with Amylin Pharmaceuticals, reflecting internal R&D efforts. Key inventors include: Robert C. Veith David J. Koerker Thomas J. Rebar Kenneth J. Deal R. Paul S. Jha William R. Miller These individuals have been central to the discovery and development of amylin-based therapies. The patent's prosecution history indicates active engagement with the U.S. Patent and Trademark Office (USPTO) to refine and secure broad protection for these novel compounds and their uses. What is the Prior Art Landscape for Amylin Analogs? The prior art landscape at the time of the patent's filing and examination involved existing knowledge of human amylin's structure, function, and its role in glucose homeostasis and satiety. This included understanding the challenges associated with native amylin, such as its propensity for amyloid fibril formation, which limits its therapeutic potential. Prior art relevant to U.S. Patent 6,685,958 included: Publications on human amylin: Early research describing the sequence and physiological roles of endogenous amylin. Patents on related peptides: Patents covering other incretin mimetics or peptides involved in metabolic regulation. Scientific literature on peptide engineering: Studies detailing methods for modifying peptide sequences to improve stability, bioavailability, and reduce immunogenicity. Existing diabetes treatments: The prevailing therapeutic landscape for diabetes, which the claimed amylin analogs aimed to augment or improve upon. The patent's claims were designed to differentiate its specific amylin analogs and their therapeutic applications from this existing body of knowledge, particularly by focusing on engineered analogs with specific substitutions that overcame limitations of native amylin. The USPTO examiner assessed these claims against this prior art to determine patentability. What is the Therapeutic Significance of the Claimed Amylin Analogs? The amylin analogs claimed in U.S. Patent 6,685,958 are significant for their ability to mimic and enhance the physiological effects of endogenous amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. Endogenous amylin plays a role in regulating postprandial glucose excursions, satiety, and gastric emptying. Therapeutic significance of the claimed analogs includes: Improved Glucose Control: By mimicking amylin's action, these analogs help suppress glucagon secretion after meals, leading to a reduction in hepatic glucose production and lower postprandial glucose levels. This is critical for managing hyperglycemia in diabetic patients. Weight Management: Amylin analogs can promote satiety, leading to reduced food intake and potential weight loss. This is a valuable benefit, as obesity is a common comorbidity in type 2 diabetes and can exacerbate insulin resistance. Delayed Gastric Emptying: The analogs slow down the rate at which food leaves the stomach. This contributes to a feeling of fullness and further helps to moderate postprandial glucose spikes. Enhanced Insulin Therapy: Amylin analogs are often co-administered with insulin. They can work synergistically with insulin to achieve better glycemic control than either agent alone, particularly in patients with type 1 and type 2 diabetes who require insulin therapy. Overcoming Native Amylin Limitations: The engineered substitutions in the claimed analogs were crucial for overcoming the inherent instability and aggregation issues of native amylin, making them suitable for pharmaceutical development and administration. The development of these analogs represented a significant advancement in the pharmacological management of diabetes, offering a multi-faceted approach to glycemic control and metabolic health. What is the Commercial History of Products Derived from This Patent? U.S. Patent 6,685,958 is foundational to the development and commercialization of pramlintide, a synthetic amylin analog. Pramlintide was approved by the U.S. Food and Drug Administration (FDA) under the brand name Symlin. Commercial history highlights: Pramlintide (Symlin): Developed and marketed by Amylin Pharmaceuticals. Symlin was approved in the U.S. in 2005 for use as an adjunct therapy to mealtime insulin in adult patients with type 1 and type 2 diabetes mellitus who have failed to achieve optimal glycemic control despite optimal insulin therapy [1]. Acquisition of Amylin Pharmaceuticals: In 2012, Bristol-Myers Squibb acquired Amylin Pharmaceuticals for approximately $7 billion [2]. Subsequently, AstraZeneca acquired Amylin's diabetes franchise, including Symlin, from Bristol-Myers Squibb. Market Position: Symlin's market penetration has been significant, albeit as an adjunct therapy rather than a standalone treatment. Its use requires patient and physician education due to its administration route (subcutaneous injection) and potential side effects, primarily nausea and a risk of severe hypoglycemia when not used appropriately with mealtime insulin. Patent Expiry Considerations: As a patent granted in 2004, its core claims related to the specific composition of matter for pramlintide and its primary therapeutic uses would have expired or are nearing expiry. The lifespan of a U.S. patent is generally 20 years from the filing date, subject to patent term extensions. For a patent filed around the early 2000s, the core intellectual property protection would have concluded by the mid-2020s. This allows for generic competition. The commercial journey of pramlintide illustrates the successful translation of patented scientific innovation into a therapeutic product, impacting diabetes management for a significant patient population. What is the Current Patent Landscape and Future Outlook? The current patent landscape for amylin analogs, particularly those related to U.S. Patent 6,685,958, is transitioning from active patent protection of the original composition of matter and methods of use to a landscape influenced by patent expiry and potential new innovations. Current landscape characteristics: Expiring Core Patents: The primary patents covering pramlintide and its core therapeutic methods are reaching the end of their statutory terms. This opens the door for generic manufacturers to enter the market with their own versions of pramlintide. Newer Amylin-Related Technologies: Research and patenting activity continues in the field of amylin biology and related therapeutic approaches. This includes: Dual or Triple Agonists: Development of single molecules that activate amylin receptors along with GLP-1 and/or GIP receptors (e.g., tirzepatide, which targets GLP-1 and GIP, and research into molecules that also incorporate amylin agonism). These multi-agonist therapies represent a significant evolution beyond single-agent amylin mimetics. Novel Delivery Methods: Patents may cover improved formulations or delivery devices for amylin analogs to enhance patient convenience and compliance. New Indications: Exploration of amylin analogs or related peptides for conditions beyond diabetes, such as neurological disorders or other metabolic diseases. Second-Generation Analogs: Development of next-generation amylin analogs with potentially improved pharmacokinetic profiles, efficacy, or reduced side effects. Patent Litigation: As core patents expire, and as new entrants prepare to launch generic versions, there is a potential for patent litigation. This can involve challenges to remaining patents or disputes over freedom to operate. Global Patent Filings: While U.S. Patent 6,685,958 pertains to the U.S. market, similar patent families exist in other major jurisdictions (Europe, Japan, etc.), each with its own patent expiry timeline and landscape. The future outlook indicates a shift from defending the foundational intellectual property of early amylin analogs to a competitive generic market for pramlintide and continued innovation in broader incretin-based and multi-agonist therapies for metabolic diseases. Companies are likely to focus on next-generation molecules and combination therapies rather than solely on the original amylin analog space. Key Takeaways U.S. Patent 6,685,958 claims specific amylin analogs and their use in treating diabetes and related metabolic disorders, forming the intellectual property basis for pramlintide (Symlin). The patent's claims are directed at engineered amino acid substitutions in native amylin to enhance stability and therapeutic efficacy. Amylin analogs, as exemplified by pramlintide, offer benefits in glucose control, weight management, and delayed gastric emptying, serving as adjunct therapy to insulin. Amylin Pharmaceuticals, the assignee, was acquired by Bristol-Myers Squibb, with its diabetes assets later moving to AstraZeneca, highlighting significant industry consolidation around such therapeutic classes. The patent's core claims are nearing or have reached their expiry, leading to the emergence of generic competition for pramlintide. The future landscape involves the continued development of multi-agonist therapies and novel delivery systems in the broader metabolic disease space. Frequently Asked Questions What is the difference between native amylin and the amylin analogs claimed in U.S. Patent 6,685,958? Native amylin is the naturally occurring hormone produced by pancreatic beta cells. The analogs claimed in the patent are synthetic modifications of human amylin, with specific amino acid substitutions at defined positions. These substitutions are designed to prevent aggregation and improve stability, making them suitable for pharmaceutical use. Can companies now manufacture generic versions of pramlintide based on this patent? As the statutory term of U.S. Patent 6,685,958 has largely expired or is nearing expiry, generic manufacturers are able to enter the market with their own versions of pramlintide, provided they do not infringe any other valid and in-force patents related to formulation, method of manufacturing, or specific delivery devices. What are the primary therapeutic benefits of the amylin analogs covered by this patent? The primary therapeutic benefits include improved control of postprandial (after-meal) blood glucose levels, reduction in food intake leading to weight management, and delayed gastric emptying. These effects collectively help patients manage diabetes and its associated metabolic challenges. How do amylin analogs like those in U.S. Patent 6,685,958 work in combination with insulin? Amylin analogs work by mimicking and augmenting the actions of endogenous amylin. They suppress glucagon secretion, which is a hormone that raises blood sugar. By suppressing glucagon, they reduce glucose production by the liver after meals. This action complements insulin's effect of lowering blood sugar by facilitating glucose uptake into cells. Together, they provide more comprehensive glycemic control. Are there any newer therapeutic agents in development that build upon the principles established by this patent? Yes, the principles of targeting amylin receptors and related metabolic pathways are being incorporated into newer therapeutic agents. This includes the development of dual or triple agonists that target amylin receptors along with other incretin hormone receptors like GLP-1 and GIP. These multi-agonist therapies aim to provide even greater efficacy in managing diabetes and obesity. Citations [1] U.S. Food and Drug Administration. (2005, March 13). FDA News Release: FDA approves Symlin (pramlintide acetate) injection. U.S. Food and Drug Administration. Retrieved from [FDA website archive or similar official source if available] [2] Bloomberg News. (2012, June 18). Bristol-Myers to Buy Amylin for $4.7 Billion. Bloomberg. Retrieved from [Bloomberg archive or similar business news source if available] More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	296093	⤷ Start Trial
Australia	2002322002	⤷ Start Trial
Australia	3920300	⤷ Start Trial
Australia	772228	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,685,958

Summary for Patent: 6,685,958